Business
Proposed Acquisition of Lyramid Pty Limited
Proposed Acquisition of Lyramid Pty Limited.
About this update from Coiled Therapeutics Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 7509S\n Roquefort Investments PLC\n 18 November 2021\n \n \n \n \n NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, ANY MEMBER STATE OF THE EEA (OTHER THAN THE UNITED KINGDOM) OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF THAT JURISDICTION\n \n \n \n \n \n 18 November 2021\n \n \n \n \n \n Roquefort Investments plc\n \n \n (\"Roquefort Investments\" or the \"Company\")\n \n \n \n \n \n Proposed Acquisition of Lyramid Pty Limited \n \n \n Proposed Placing of up to 30,000,000 Ordinary Shares of £0.01 each at £0.10 per Ordinary Share \n \n \n Proposed Change of Name \n \n \n \n \n \n Roquefort Investments plc (\n LSE:ROQ\n ), the \n investment company established to acquire businesses focused on early-stage opportunities in the medical biotechnology sector\n , is pleased to announce that further to the announcement of 29 September 2021, the Company has now entered into a conditional share sale and purchase agreement (the \"Acquisition Agreement\") with Provelmare Holding S.A. (the \"Seller\") pursuant to which Roquefort Investments has agreed to acquire the entire issued share capital of Lyramid Pty Limited (\"Lyramid\") for an initial consideration of £1 million payable 50% in cash and 50% in shares (the \"Acquisition\"). \n \n \n \n \n \n Lyramid has the exclusive worldwide licence to commercialise up to 37 patents related to Midkine-based therapies for the treatment of COVID-19 patients, cancer, autoimmune disorders and chronic inflammation (\"Midkine-Based Therapies\").\n \n \n \n \n \n The Directors of Roquefort Investments consider the \n Acquisition \n to represent a transformational, value enhancing transaction for shareholders, which is fully aligned with the Company's growth strategy. Lyramid's global patent portfolio for Midkine-Based Therapies provides a platform to develop first-in-class drugs for the treatment of severe inflammatory diseases, autoimmune disorders and cancer. The therapeutic potential of Midkine-Based Therapies has been validated during more than 10 years of research including collaborations with leading academic centres and clinicians resulting in over 900 scientific publicatio...